ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Clinically relevant positive reactions to clotrimazole cream and purified ... commonly used as a topical treatment of vaginal candidiasis, seborrheic dermatitis, and tinea pedis.

PHAT is a facial rejuvenation therapy that combines nanofat and its stem cells with PRP for anti-aging that lasts for more ...

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

If the patient has reported a history of steroid use, the first treatment step should be to ... (10/0 hydrocortisone or desonide cream) or topical calcineurin inhibitors (1% pimecrolimus) may ...

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.